Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 38 Records) |
| Query Trace: Atrial Fibrillation and ABCB1[original query] |
|---|
| Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect. Frontiers in pharmacology 2018 9 491. Gu Zhi-Chun, Ma Xiao-Wei, Zheng Xiao-Yuan, Shen Long, Shi Fang-Hong, Li H |
| Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and personalized medicine 2018 4 11 43-49. Kryukov Alexander Valerevich, Sychev Dmitry Alekseevich, Andreev Denis Anatolevich, Ryzhikova Kristina Anatolievna, Grishina Elena Anatolievna, Ryabova Anastasia Vladislavovna, Loskutnikov Mark Alekseevich, Smirnov Valeriy Valerevich, Konova Olga Dmitrievna, Matsneva Irina Andreevna, Bochkov Pavel Olegovi |
| Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. British journal of clinical pharmacology 2018 Feb . Ueshima Satoshi, Hira Daiki, Kimura Yuuma, Fujii Ryo, Tomitsuka Chiho, Yamane Takuya, Tabuchi Yohei, Ozawa Tomoya, Itoh Hideki, Ohno Seiko, Horie Minoru, Terada Tomohiro, Katsura Toshi |
| Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. Journal of thrombosis and thrombolysis 2019 Sep . Gulilat Markus, Keller Denise, Linton Bradley, Pananos A Demetri, Lizotte Daniel, Dresser George K, Alfonsi Jeffrey, Tirona Rommel G, Kim Richard B, Schwarz Ute |
| Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. Medicine 2020 9 99 (36): e22084. Wu Tingting, Xia Xiaotong, Fu Jinglan, Chen Wenjun, Zhang Jinh |
| Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation. Basic & clinical pharmacology & toxicology 2020 Sep . Nakagawa Junichi, Kinjo Takahiko, Iizuka Mei, Ueno Kayo, Tomita Hirofumi, Niioka Takeno |
| Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug metabolism and personalized therapy 2020 Mar . Sychev Dmitriy, Skripka Alena, Ryzhikova Kristina, Bochkov Pavel, Shevchenko Roman, Krupenin Pavel, Ivashchenko Dmitriy, Kogay Veronika, Listratov Alexander, Krainyaya Arina, Gurinovich Olga, Sokolova Anastasiya, Napalkov Dmitriy, Fomin Vikt |
| CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. Pharmacogenomics and personalized medicine 2020 3 13 29-37. Sychev D A, Baturina O A, Mirzaev K B, Rytkin E, Ivashchenko D V, Andreev D A, Ryzhikova K A, Grishina E A, Bochkov P O, Shevchenko R |
| The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. British journal of clinical pharmacology 2020 Nov . Ji Qiuyi, Zhang Chunyu, Xu Qing, Wang Zi, Li Xiaoye, Lv Qianzh |
| MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug metabolism and personalized therapy 2021 8 . Rytkin Eric, Bure Irina V, Bochkov Pavel O, Akmalova Kristina A, Mirzaev Karin B, Cherniaeva Marina S, Ostroumova Olga D, Smirnov Valery V, Grishina Elena A, Saribekian Anna G, Sychev Igor N, Sychev Dmitry |
| Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation. Frontiers in pharmacology 2021 5 12 639854. Wang Yan, Chen Min, Chen Hui, Wang Fa |
| Associations among plasma concentrations of edoxaban and M-4, prothrombin time, and the SLCO1B1*15 haplotype in patients with non-valvular atrial fibrillation. Therapeutic drug monitoring 2022 Sep . Nakagawa Junichi, Kinjo Takahiko, Aiuchi Naoya, Ueno Kayo, Tomita Hirofumi, Niioka Takeno |
| Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation. Biopharmaceutics & drug disposition 2022 Aug 43 (4): 163-171. Zhang Dan, Qin Wei, Du Wenwen, Wang Xiaoxing, Chen Wenqian, Li Pengm |
| The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension 2022 Aug . Sychev Dmitry, Ostroumova Olga, Cherniaeva Marina, Shakhgildian Nataliia, Mirzaev Karin, Abdullaev Sherzod, Denisenko Natalia, Sozaeva Zhannet, Kachanova Anastasia, Gorbatenkova Svetlana, Shastina Ve |
| MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug metabolism and personalized therapy 2022 4 37 (1): 41-46. Rytkin Eric, Bure Irina V, Bochkov Pavel O, Akmalova Kristina A, Mirzaev Karin B, Cherniaeva Marina S, Ostroumova Olga D, Smirnov Valery V, Grishina Elena A, Saribekian Anna G, Sychev Igor N, Sychev Dmitry |
| Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study. Clinical pharmacokinetics 2022 3 61 (6): 881-893. Zhang Feilong, Chen Xuehai, Wu Tingting, Huang Nianxu, Li Li, Yuan Dongdong, Xiang Jing, Wang Na, Chen Wenjun, Zhang Jinh |
| Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients. Frontiers in pharmacology 2022 12 13 1007113. Campos-Staffico Alessandra M, Dorsch Michael P, Barnes Geoffrey D, Zhu Hao-Jie, Limdi Nita A, Luzum Jasmine |
| Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation. European journal of clinical pharmacology 2022 11 79 (1): 127-135. Nakagawa Junichi, Kinjo Takahiko, Aiuchi Naoya, Ueno Kayo, Tomita Hirofumi, Niioka Takeno |
| The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation. BMC cardiovascular disorders 2022 11 22 (1): 481. Zhu Zhu, Qian Chenyue, Su Cunjing, Tao Hong, Mao Jiaojiao, Guo Zhening, Zhu Xinyi, Pan J |
| Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events. Frontiers in genetics 2022 10 13 982955. Attelind Sofia, Hallberg Pär, Wadelius Mia, Hamberg Anna-Karin, Siegbahn Agneta, Granger Christopher B, Lopes Renato D, Alexander John H, Wallentin Lars, Eriksson Nicl |
| Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice. Pharmacogenetics and genomics 2022 Oct . Sychev Dmitry Alekseevitch, Sokolov Aleksey Vladimirovich, Reshetko Olga Vilorovna, Fisenko Vladimir Petrovich, Sychev Igor Nikolaevich, Grishina Elena Anatolievna, Bochkov Pavel Olegovich, Shevchenko Roman Vladimirovich, Abdullaev Sherzod Pardaboevich, Denisenko Natalia Pavlovna, Ivashchenko Dmitry Vladimirovich, Sozaeva Zhannet Alimovna, Kachanova Anastasia Alekseev |
| ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban. Drug design, development and therapy 2023 8 17 2513-2522. Hamin Kim, Tae-Jin Song, Jeong Yee, Dong-Hyeok Kim, Junbeom Park, Hye Sun Gw |
| The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation. Human genomics 2023 7 17 (1): 59. Tingting Wu, Shuyi Wu, Li Li, Jing Xiang, Na Wang, Wenjun Chen, Jinhua Zha |
| The Distribution of the Genotypes of ABCB1 and CES1 Polymorphisms in Kazakhstani Patients with Atrial Fibrillation Treated with DOAC. Genes 2023 6 14 (6): . Ayan Abdrakhmanov, Ainur Akilzhanova, Aizhan Shaimerdinova, Madina Zhalbinova, Gulnara Tuyakova, Svetlana Abildinova, Rustam Albayev, Bayan Ainabekova, Assel Chinybayeva, Zhanasyl Suleimen, Makhabbat Bekbossyno |
| Genetic variants of ABCB1 and CES1 genes on dabigatran metabolism in the Kazakh population. Caspian journal of internal medicine 2024 7 15 (3): 499-508. Ayan Abdrakhmanov, Elena Zholdybayeva, Aizhana Shaimerdinova, Gulmira Kulmambetova, Svetlana Abildinova, Rustam Albayev, Gulnara Tuyakova, Elena Rib, Zhanasyl Suleimen, Zhanar Abdrakhmanova, Makhabbat Bekbossyno |
| The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation. Drug metabolism and personalized therapy 2024 6 . Alena I Skripka, Pavel M Krupenin, Olga N Kozhanova, Anna A Kudryavtseva, Ludmila V Fedina, Kristina A Akmalova, Pavel O Bochkov, Anastasiya A Sokolova, Dmitriy A Napalkov, Dmitriy A Sych |
| Transporter Genes and statin-induced Hepatotoxicity. Cardiovascular drugs and therapy 2024 5 . Seo-A Choi, Jung Sun Kim, Yoon-A Park, Da Hoon Lee, Minju Park, Jeong Yee, Yoonkyung Chang, Tae-Jin Song, Hye Sun Gw |
| Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants. Therapeutic advances in cardiovascular disease 2024 5 18 17539447241249886. Ayan Abdrakhmanov, Aizhana Shaimerdinova, Zhanasyl Suleimen, Svetlana Abildinova, Rustam Albayev, Gulnar Tuyakova, Elena Rib, Akmaral Beysenbayeva, Gulden Kabduyeva, Makhabbat Bekbossyno |
| Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation. Journal of clinical medicine 2024 5 13 (9): . Luca Cumitini, Giulia Renda, Mara Giordano, Roberta Rolla, Tarek Shail, Sara Sacchetti, Lorena Iezzi, Luca Giacomini, Valentina Zanotti, Raffaella Auciello, Ilaria Angilletta, Melissa Foglietta, Mirco Zucchelli, Ivana Antonucci, Liborio Stuppia, Sabina Gallina, Umberto Dianzani, Giuseppe Pat |
| Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up. Medicina (Kaunas, Lithuania) 2024 10 60 (10): . Nur Ul Ain, Niaz Ali, Abid Ullah, Shakir Ullah, Shujaat Ahm |
- Page last reviewed:Feb 1, 2024
- Content source: